High Content Screening System

The Advanced Technologies team at the Medicines Discovery Catapult (MDC) is looking to expand its current advanced microscopy facility to support both our own growing needs and provide the UK SME community access to advanced molecular and cellular imaging. MDC is aiming purchase a confocal High Content Screening (HCS) instrument based on an automated well-plate inverted microscope, together with confocal and widefield functionalities. It is crucial for the HCS system to be flexible and provide fast and high-resolution imaging of a wide range of experiments. The instrument should be configured to enable the use of different sample formats (2D and 3D cell models, tissue sections, fixed and live-cell) and experimental types (drug dose responses, live-cell kinetic studies, phenotypic screening, RNA scope), using a large variety of well-plate formats and a wide range of fluorophores. In addition, the HCS instrument must be supplied with a high-end solution for high content image analysis, visualization and handling. MDC will be publishing an RFI regarding the High Content Screening (HCS) instrument during the week commencing 05/09/2022, if you wish to be involved please email procurement@md.catapult.org.uk referencing this PIN. This prior information notice (PIN) is a signal of future intentions to the marketplace regarding the procurement of equipment for the confocal High Content Screening (HCS) instrument. This PIN is not a call for competition. By publishing this PIN, MDC may avail itself of the opportunity to reduce the submission period from 30 days (with electronic submission) to 15 days (if the PIN has been published for at least 35 days and no longer than 12 months).